GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » EV-to-Revenue

CBIO (Crescent Biopharma) EV-to-Revenue : (As of Jun. 24, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Crescent Biopharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Crescent Biopharma's enterprise value is $301.07 Mil. Crescent Biopharma does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Crescent Biopharma's EV-to-Revenue at this moment.

The historical rank and industry rank for Crescent Biopharma's EV-to-Revenue or its related term are showing as below:

CBIO's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.6
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-24), Crescent Biopharma's stock price is $15.065. Crescent Biopharma does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024. Therefore, GuruFocus does not calculate Crescent Biopharma's PS Ratio at this moment.

Crescent Biopharma EV-to-Revenue Historical Data

The historical data trend for Crescent Biopharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Crescent Biopharma EV-to-Revenue Chart

Crescent Biopharma Annual Data
Trend Dec24
EV-to-Revenue
-

Crescent Biopharma Quarterly Data
Dec24
EV-to-Revenue -

Competitive Comparison of Crescent Biopharma's EV-to-Revenue

For the Biotechnology subindustry, Crescent Biopharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Crescent Biopharma's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's EV-to-Revenue falls into.


;
;

Crescent Biopharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Crescent Biopharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=301.066/
=

Crescent Biopharma  (NAS:CBIO) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Crescent Biopharma's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=15.065/
=

Crescent Biopharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Crescent Biopharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Crescent Biopharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Crescent Biopharma Inc (NAS:CBIO) » Definitions » EV-to-Revenue
Comparable Companies
Traded in Other Exchanges
N/A
Address
221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Website
https://www.crescentbiopharma.com
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.